Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementAetna CRPS/RSD Treatments Coverage Update | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0447

    Complex Regional Pain Syndrome (CRPS) / Reflex Sympathetic Dystrophy (RSD): Treatments

    Customize your policy alerts

    Sign up for Aetna Policy 0447 alerts

    Get alerted when Policy 0447 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, experimental/investigational determinations, and coding guidance for treatments of CRPS/RSD affecting members covered by Aetna when specified criteria are met.

    Policy Summary
    PayerAetna
    PolicyComplex Regional Pain Syndrome (CRPS) / Reflex Sympathetic Dystrophy (RSD): Treatments
    Policy CodePolicy 0447
    Change TypeNo material change
    Effective DateSep 14, 2000
    Last ReviewFeb 27, 2024
    Next Review DateMay 9, 2024
    Key ActionDocument prior conservative therapy failure and trial stimulation success when requesting advanced interventions (e.g., DRG stimulation).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Up to 3sympathetic blocks (initial)
    7 daysminimum interval for repeats
    4-6 dayscontinuous epidural typical stay
    41 RCTsrandomized trials identified
    81.2%DRG >=50% pain relief (ACCURATE)
    02/27/2024last review date

    Coverage Criteria for CRPS / RSD Treatments

    Continuous epidural analgesia - Medical necessity

    Continuous epidural analgesia is considered medically necessary when ALL of the following are met:

    Continuous epidural analgesia selection criteria: Members have experienced pain for more than 3 months despite conservative therapy (e.g., exercises, physical modalities, and medications); AND Members have failed a trial of physical therapy; AND Members have failed a trial of nerve blocks with local anesthetics and steroids.

    If criteria not met, continuous epidural analgesia is considered experimental/investigational.

    Sympathetic blocks - Medical necessity and limits

    Sympathetic blocks are considered medically necessary when the following conditions are met:

    Sympathetic blocks criteria: Sympathetic blocks (e.g., stellate ganglion, lumbar sympathetic) are for diagnosis and treatment of sympathetically-maintained pain and/or CRPS after failure of conservative treatments (including analgesia and physical therapy). Up to 3 sympathetic blocks are medically necessary to diagnose/achieve therapeutic effect; if no relief after 3 injections, additional injections are not medically necessary. Repeat sympathetic blocks beyond the first 3 are medically necessary only when provided as part of a comprehensive pain management program including PT, patient education, psychosocial support, and oral medications as appropriate; and blocks should not be repeated more frequently than once every 7 days.
    Policy Summary
    PayerAetna
    PolicyComplex Regional Pain Syndrome (CRPS) / Reflex Sympathetic Dystrophy (RSD): Treatments
    Policy CodePolicy 0447
    Change TypeNo material change
    Effective DateSep 14, 2000
    Last ReviewFeb 27, 2024
    Next Review DateMay 9, 2024
    Key ActionDocument prior conservative therapy failure and trial stimulation success when requesting advanced interventions (e.g., DRG stimulation).
    SourceLink
    On This Page
    Coverage Criteria for CRPS / RSD TreatmentsCoding and Billing GuidanceProvider Actions, Prior Authorization and DocumentationDefinitions and Diagnostic CriteriaConservative Treatment and PrerequisitesFrequency and Quantity LimitsImaging and Procedural GuidanceNot Covered / Experimental TherapiesBackground and Evidence OverviewPolicy Revision History
    max 3 initial injections; not more frequently than once every 7 days

    Abandon if immediate response not observed after first or second block per guidance.

    Neurostimulation

    Dorsal column stimulators (spinal cord stimulation) and related neuromodulation:

    Neurostimulation (DCS/DRGS) criteria: Dorsal column stimulators (DCS/SCS) are considered medically necessary DME for management of CRPS when the member meets all criteria listed in CPB 0194 - Spinal Cord Stimulation. For dorsal root ganglion stimulation (DRGS) for CRPS, refer to CPB 0194; documentation should include prior conservative management failure and successful trial stimulation prior to permanent implant.

    Refer to CPB 0194 for full device-specific criteria; trial stimulation outcome required for implant requests.

    Experimental / Investigational

    Interventions considered experimental and investigational (partial list):

    Experimental/Investigational interventions: Intravenous guanethidine; ketamine including prolonged anesthetic-dose 'ketamine coma'; lidocaine; midazolam; intrapleural analgesia; neurolysis of the spinal accessory nerve; amputation for pain relief; Bier block; BEMER magneto-therapy; bisphosphonates; botulinum toxin; combined DRG and DCS; combined tDCS and TENS; compression sleeve; electroconvulsive therapy; exergame therapy; free-flap surgery and vein wrapping; hypnosis; intrathecal adenosine; intrathecal baclofen; intrathecal clonidine; intrathecal corticosteroid; intravenous immunoglobulin (IVIG); intravenous magnesium; intravenous propofol infusion; ketamine metabolite (2R,6R)-hydroxynorketamine; metformin; movement representation techniques; multi-site continuous peripheral nerve catheters; mycophenolate; neuroplasty; occlusal splint; oral memantine; prism adaptation; pulsed light therapy; pulsed radiofrequency; radiofrequency sympathetic neurotomy; Sanexas electroanalgesia; tadalafil; thalidomide; topical ketamine; transcranial direct current stimulation; transcranial magnetic stimulation; TNF-alpha antagonists; ultrasound-guided percutaneous PNS; virtual body swapping — effectiveness not established for CRPS in current evidence.

    See policy text for complete list and trial-level limitations.

    General coverage criteria (interpretive)

    Covered when ALL of the following are met (interpretive — based on evidence summaries in document):

    General coverage conditions: Patient has a diagnosis of CRPS confirmed by Budapest Criteria; conservative therapies (analgesics, physical/occupational therapy, movement representation techniques where appropriate) have been attempted and documented as failed; selected interventions have supportive evidence from RCTs or higher-quality studies for the indication; and clinical documentation demonstrates prior therapies, objective baseline pain/function measures, trial stimulation results (for device therapies), and rationale for selected intervention.

    Derived from guideline and evidence summaries; documentation of prior conservative treatment failure and trial results is required for advanced interventions.

    Ketamine — evidence summary

    Evidence-based efficacy statements (study-level findings):

    Ketamine infusions — evidence summary: Multiple small RCTs and cohort studies report that multi-day low-dose IV ketamine infusions produce significant short-term pain reduction in some patients (e.g., Sigtermans et al. 4.2-day infusion showed lower pain scores over 12 weeks with loss of significance by week 12). Meta-analysis indicates immediate pain relief event rate ~69% and 1–3 month relief ~58%, but heterogeneity and limited duration of effect are noted; functional improvement was not demonstrated consistently.benefit typically <3 months

    Dosing and duration vary across studies; document prior conservative therapy failure and monitoring during infusion.

    Bisphosphonates

    Bisphosphonates:

    Bisphosphonate findings: Randomized trials and a systematic review of bisphosphonates in CRPS-1 with bone loss reported pooled VAS pain reductions (~21–22 mm) at 4 and 12 weeks in included trials, suggesting potential short-term pain benefit; however evidence is limited and not sufficient for broad practice-wide recommendation.

    Further randomized trials are needed; monitor for adverse effects associated with bisphosphonates.

    Interventional therapies

    Neuromodulation and procedural interventions:

    Spinal cord stimulation: Randomized trials indicate that SCS plus physical therapy can produce short-term pain benefit versus PT alone; long-term (5-year) differences may attenuate, though subsets with permanent implants reported greater perceived effect. Device selection should follow CPB 0194 criteria and include successful trial stimulation prior to permanent implantation.

    Efficacy may diminish over time; document trial and implant outcomes.

    Lumbar sympathectomy / RF neurolysis: Pilot randomized data comparing RF lumbar sympathectomy to phenol neurolysis showed within-group pain reductions but no between-group difference; larger trials are required to confirm effectiveness.

    Evidence limited to small pilot trials.

    IVIG

    Immunologic therapy:

    IVIG evidence summary: A small randomized cross-over trial (Goebel et al.) of low-dose IVIG (0.5 g/kg) showed reduced pain versus saline in refractory long-standing CRPS, but limitations (small sample, potential blinding issues, incomplete prior therapy trials) limit generalizability; larger trials are needed before routine endorsement.

    Study-level result; not sufficient for broad coverage without additional evidence.

    Coverage stance and clinical considerations

    Coverage considerations reflected by guideline statements and reviews in the document

    Conservative therapy before intervention: Guidance and systematic reviews emphasize that conservative management (analgesia and physical therapy) should be attempted and documented as failed prior to considering sympathetic blocks, sympathectomy, or other invasive interventions; an initial trial of up to three sympathetic blocks may be used diagnostically/therapeutically but should be abandoned if immediate response is not observed.up to 3 blocks

    Stated in UpToDate and state workers' compensation guidance (Washington State, Colorado).

    Sympathectomy caution: Surgical or chemical sympathectomy should be used cautiously and generally only after failure of other options because high-quality evidence is lacking.case-by-case

    Cochrane review identified very limited randomized data.

    Evidence summaries and considerations

    Evidence and clinical findings relevant to consideration of these therapies:

    Ketamine infusion considerations: Meta-analyses and RCTs show ketamine infusions can provide statistically significant short-term pain reduction in CRPS (immediate relief event rate ~69%, 1–3 month relief ~58%), but heterogeneity, variable dosing regimens, small sample sizes, and limited-duration effects (<3 months) are consistent concerns; functional improvement is inconsistently demonstrated.evidence strength: small RCTs/cohorts; benefit typically <3 months

    Document prior conservative therapy failure and informed consent; monitoring protocols used in trials should be followed.

    Intrathecal agents (adenosine/clonidine): Single small randomized crossover study showed intrathecal clonidine (100 μg) had larger effect on pain over time than adenosine (2 mg) though primary outcome did not differ; evidence is limited and not supported as standard therapy in UpToDate.single small RCT evidence

    Not widely endorsed as standard therapy.

    Movement representation techniques: Mirror therapy and graded motor imagery have low to very low quality evidence from systematic reviews and RCTs suggesting possible pain and disability reduction in CRPS-I; these represent conservative, low-risk options prior to invasive therapies.evidence quality: low/very low

    Optimal type and dosing not established.

    Dorsal Root Ganglion Stimulation (DRGS): Observational cohorts and the ACCURATE randomized comparative trial demonstrate substantial pain reduction with DRGS for lower-extremity CRPS, with cohort mean pain reductions reported (e.g., ~56% at 12 months) and ACCURATE showing higher treatment success versus DCS; trial stimulation success is recommended before permanent implantation.trial stimulation recommended; >=50% VAS reduction used in ACCURATE

    Largest RCT supports DRGS for lower-extremity CRPS but further independent studies are advised.

    DRG stimulation — study-based criteria

    Evidence summary notes (not formal coverage criteria):

    DRG stimulation evidence: The ACCURATE randomized trial (n=152) demonstrated greater treatment success for DRGS versus dorsal column stimulation at 3 months (>=50% VAS reduction: 81.2% DRG vs 55.7% DCS) with sustained improvements in QOL and no increased stimulation-related neurological deficits; trial stimulation and documentation of success are key endpoints for device implantation requests.>=50% VAS reduction

    Largest RCT evidence supports DRGS for lower-extremity CRPS; further RCTs recommended.

    Evidence summaries for investigational/adjunctive therapies

    Summary of evidence-based and investigational therapies (no explicit cover/not-cover decisions in this excerpt):

    Mycophenolate: Randomized open proof-of-concept trial (N=12, 9 analyzable) suggested mycophenolate reduced pain in a subgroup but high discontinuation due to side effects; definitive trials are needed.

    Feasibility data only.

    Topical ketamine: Retrospective series (n=16) reported mixed outcomes (approximately half improved, some worsened) with no adverse effects recorded; prospective controlled studies are needed to establish efficacy.

    Limited retrospective data.

    Combined DRG and DCS: Small case series (n=4) reported further improvement using combined DRG and dorsal column SCS versus either alone; authors call for prospective studies to evaluate combination therapy.

    Preliminary case-series evidence only.

    tDCS + TENS: Single-case report suggests slight pain reduction with combined tDCS and TENS; evidence insufficient to support routine use.

    Case-level evidence.

    Exergame therapy: Feasibility study (n=10) for hand CRPS reported acceptable usability but no significant pain change; larger RCTs required to assess clinical benefit.

    Feasibility data only.

    Sanexas electroanalgesia: Device described but lacking peer-reviewed evidence; UpToDate review does not mention electroanalgesia indicating insufficient evidence for clinical use.

    Insufficient peer-reviewed data.

    Ultrasound-guided percutaneous PNS: Case report showed marked pain reduction and functional improvement after percutaneous PNS implantation; larger series or trials are needed.

    Single-case evidence.

    Intravenous propofol: Evidence is limited and indirect; UpToDate does not list propofol for CRPS treatment; data insufficient for recommendation.

    Insufficient evidence.

    Prism adaptation: Double-blind RCT (n=49) of prism adaptation for upper-limb CRPS-I found no benefit over sham; prism adaptation is not supported by this RCT.

    Negative RCT.

    Hypnosis: Scoping review and group hypnosis studies suggest potential pain and QOL benefits for neuropathic pain including CRPS, but methodological limitations and small samples limit conclusions and further controlled trials are needed.

    Preliminary encouraging but low-quality evidence.

    Amputations and major surgical procedures listed in the coding tables (for example, interthoracoscapular forequarter amputation and multiple limb amputation codes) are not supported as treatments for CRPS when performed for the purpose of pain relief. The policy references surgical amputation codes and specific not-covered CPTs and states that amputation for pain relief may worsen CRPS and is not recommended as routine therapy; amputation should be considered only in exceptional circumstances such as intractable infection or other dire indications documented in the medical record.

    The evidence base for many therapies reviewed is limited, and interventions without supportive randomized controlled trial data or with negative/insufficient trial results are not supported for routine coverage. The systematic review identified 41 RCTs but concluded that only a few interventions (notably bisphosphonates in selected patients) have clear benefits; other agents and approaches (for example, calcitonin, vasodilators, and certain sympatholytic IV regional blockade) have not demonstrated consistent benefit and therefore are not supported by the available RCT evidence.

    Surgical amputation for the primary purpose of pain relief in CRPS is discouraged. The Royal College of Physicians guidance and the policy state that amputation may worsen CRPS and can lead to recurrence in the stump; therefore amputation should only be considered in rare, exceptional circumstances (for example, intractable infection) with careful patient selection and documentation.

    Certain devices and intrathecal agents are not supported as standard therapies. A widely used clinical reference (UpToDate) does not mention the use of compression sleeves as a management tool for CRPS, and intrathecal adenosine and intrathecal clonidine are not described as standard therapeutic options in that review. These items therefore are not recommended as routine management based on the cited clinical summaries.

    Randomized trial evidence does not support routine use of low-dose intravenous immunoglobulin (0.5 g/kg) for long-standing moderate-to-severe CRPS. A multicenter, double-blind RCT (n=111) found no significant difference in average pain between IVIG and placebo over the primary outcome interval; thus routine use of low-dose IVIG for long-standing CRPS is not supported by that trial.

    The policy emphasizes a conservative-first approach: therapies not described as standard in UpToDate or guideline reviews should be considered investigational or adjunctive until further high-quality evidence is available. Several interventions summarized in the literature are either experimental or have limited/uncertain benefit and therefore should not be considered standard care without further evidence and appropriate documentation of prior conservative management.

    Sympathetic (stellate or lumbar) blocks may be used as a diagnostic or short-term therapeutic trial, but repetition beyond the initial trial is limited. The policy supports up to 3 initial sympathetic blocks to establish diagnosis or therapeutic effect, and states that additional injections beyond these are not medically necessary unless provided as part of a documented comprehensive pain management program. Repeat sympathetic blocks should not be performed more frequently than once every 7 days.

    A number of interventions summarized in the review lack supportive evidence from well-designed randomized trials and are therefore considered investigational or not medically necessary. Examples include prolonged anesthetic-dose 'ketamine coma' and various novel or device-based approaches for which peer-reviewed efficacy data are insufficient; such interventions may be declined or require additional justification and documentation of prior therapies.

    Botulinum toxin injected intradermally or subcutaneously into allodynic skin did not improve pain and was poorly tolerated in a pilot study. The trial reported no significant benefit and limited tolerability, and therefore botulinum toxin for this indication is not supported by the available evidence.

    Transcranial direct current stimulation (tDCS) added to graded motor imagery did not provide additional pain reduction compared with GMI plus sham in a small randomized proof-of-concept study; evidence is insufficient to support routine coverage of tDCS for CRPS at this time.

    Prism adaptation treatment was evaluated in a double-blind randomized controlled trial (n=49) for upper-limb CRPS‑I and showed no benefit over sham treatment. Improvement over time occurred in both groups, but PA did not demonstrate efficacy beyond sham, and UpToDate does not list prism adaptation as a recommended therapeutic option.

    Coding and Billing Guidance

    Covered CPT/HCPCS codes if selection criteria metCPTCovered
    01996Daily hospital management of epidural or subarachnoid continuous drug administration.
    62324Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, interlaminar epidural or subarachnoid, cervical or thoracic.
    62325Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, interlaminar epidural or subarachnoid, cervical or thoracic.
    62326Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance.
    62327Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (ie, fluoroscopy or CT).
    63650Percutaneous implantation of neurostimulator electrode array, epidural.
    63655Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
    63661Removal of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed.
    63662Removal of spinal neurostimulator electrode plate/paddle(s), placed via laminotomy or laminectomy, including fluoroscopy, when performed.
    63663Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed.
    1–10 of 17
    1/2
    CPT codes not covered for indications listed (e.g., amputation, intrapleural analgesia, neuroplasty)CPTNot Covered
    23900Interthoracoscapular amputation (forequarter).
    32554Thoracentesis, needle or catheter, aspiration of pleural space; without imaging guidance.
    32555Thoracentesis, needle or catheter, aspiration of pleural space; with imaging guidance.
    64555Percutaneous implantation of neurostimulator electrode array; peripheral nerve.
    64702Neuroplasty (Exploration, Neurolysis or Nerve Decompression).
    76942Ultrasonic guidance for needle placement, imaging supervision and interpretation.
    DME / neurostimulator HCPCS codes related to policyHCPCSCovered
    L8685Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
    L8686Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension.
    L8687Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
    L8688Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension.
    L8680Implantable neurostimulator electrode, each.
    L8681Patient programmer (external) for use with implantable programmable neurostimulator pulse generator.
    ICD-10 diagnosis codes covered if selection criteria are metICD-10Covered
    G90.50Complex regional pain syndrome (CRPS I).
    G90.59Other complex regional pain syndrome.
    Drugs / injectable codes listed in policy (some associated with investigational interventions)HCPCS
    J0135Injection, adalimumab, 20 mg.
    J3475Injection, magnesium sulfate, per 500 mg.
    J3489Injection, zoledronic acid, 1 mg.
    Codes referenced in this excerptmixed
    No codes listed
    Sympathetic block trial — initial limit and conditions
    Trial limitUp to 3 sympathetic block injections to establish diagnostic or therapeutic effect; if no relief after 3 injections, additional injections are not medically necessary.
    Comprehensive program exceptionRepeat sympathetic blocks beyond the initial 3 are medically necessary only when provided as part of a comprehensive pain management program (including PT, patient education, psychosocial support, and oral medications).
    Minimum intervalBlocks should not be repeated more frequently than once every 7 days.
    Pain reduction threshold used in ACCURATE trial
    ACCURATE trial pain threshold>= 50% decrease in VAS (visual analog scale) from pre-implant baseline used as the primary pain-relief threshold in the ACCURATE randomized trial.
    Timing for assessmentPrimary endpoint assessed at 3 months post-implant in the ACCURATE trial.
    Treatment success compositeTreatment success required >=50% VAS reduction and absence of stimulation-related neurological deficits for subjects with permanent implants.

    Provider Actions, Prior Authorization and Documentation

    Prior Authorization

    Prior authorization required for listed CRPS procedure codes

    Prior authorization is required for the CPT/HCPCS codes listed in the policy when used for CRPS treatments and only when the policy’s selection criteria are met. Refer to the listed codes (e.g., 01996, 62324–62327, 63650, 63655, 63661–63664, 63685, 63688, 64479, 64510–64530, L8680–L8688, etc.) when submitting requests.

    • Prior authorization applies only when selection criteria in this Clinical Policy Bulletin are not met, or when implant/testing of neuromodulation is planned.
    • Supply documentation that demonstrates the member meets the applicable selection criteria in the policy.
    Prior Authorization

    Recommend prior authorization for high‑resource interventions

    For resource-intensive interventions (for example, multi-day ketamine infusions, spinal cord or DRG stimulation, intrathecal pumps), prior authorization is recommended and requests should document refractory disease and prior therapies attempted.

    • Include evidence of failed conservative management and rationale for escalation.
    • Resource-intensive outpatient infusions should note supervising clinician and monitoring plans.
    Prior Authorization

    Prior authorization appropriate for multi‑day IV ketamine and IV therapies

    Prior authorization is appropriate for multi-day IV ketamine infusions and other IV therapies in chronic refractory CRPS; requests should include documentation of prior conservative therapy failures and indicate the treatment is for selected, refractory patients.

    • Provide baseline pain scores and monitoring plan (e.g., continuous ECG, pulse oximetry, BP monitoring every 15 minutes as in outpatient infusion studies).
    • Document prior conservative therapy attempts and why IV therapy is being considered.
    Prior Authorization

    DRG stimulation requires prior conservative failure and trial documentation

    Dorsal root ganglion stimulation (DRGS) requests should document prior conservative management failure and evidence of a successful trial stimulation (trial outcome, targeted levels) before permanent implantation.

    • Document trial stimulation results (e.g., proportion pain relief, VAS/NRS scores) and absence of stimulation‑related neurological deficits.
    • Indicate targeted DRG levels (e.g., L2–L4 for knee CRPS) and prior conservative therapies attempted.
    Documentation Required

    Document trial stimulation success and outcome measures for DRG implantation

    When seeking permanent DRG stimulation implantation, document successful trial stimulation and provide trial‑to‑implantation outcome measures (e.g., percentage pain relief, VAS/NRS), because DRG implant decisions are supported by trial data and case series.

    • Cite trial success thresholds when available (ACCURATE trial used ≥50% VAS decrease as an efficacy threshold).
    • Include follow‑up outcome measures if prior implants/trials exist.
    Prior Authorization

    Neuromodulation implantation usually requires prior trial documentation

    Requests for implantation of neuromodulation devices (DRG stimulator, spinal cord stimulator, percutaneous PNS) typically require documentation of prior trial success and failure of conservative therapies; provide device trial data and relevant prior therapy history.

    • Attach trial stimulation reports, pain scores, and evidence of prior conservative management failure (PT, medications, etc.).
    • For novel/combined device approaches, include supporting case series or trial data when available.
    Note

    No additional authorization process specified in this excerpt

    This excerpt does not list specific plan-level prior authorization forms, portals, or additional affected codes beyond those listed in the CPT/HCPCS tables; check member benefits and utilization management procedures for any payer‑specific prior authorization processes.

    • Policy text notes that Clinical Policy Bulletins assist in administering benefits but do not guarantee coverage; follow plan-specific authorization channels.
    Documentation Required

    Document prior conservative therapy and failed PT before advanced interventions

    Providers must document trials of conservative therapy — including exercises, physical modalities, and medications — and a failed trial of physical therapy before considering continuous epidural analgesia or sympathetic interventions.

    • Document duration of pain (>3 months) and specific conservative therapies tried and their durations.
    • For sympathetic blocks, note that conservative treatments (including analgesia and PT) must have failed prior to initial trial injections.
    Documentation Required

    Document prior attempts of evidence‑backed conservative therapies

    The policy emphasizes consideration of evidence‑backed conservative therapies (e.g., bisphosphonates, motor/sensory learning programs) and documents prior attempts at these therapies before proceeding to experimental or high‑risk interventions.

    • If bisphosphonates or motor imagery programs were tried, include treatment dates, dosing, and response.
    • Explain why other evidence‑backed conservative measures were insufficient in refractory cases.
    Note

    Adopt a conservative‑first approach before interventional therapy

    Guidance reflects a conservative‑first approach: initial conservative management including analgesics and physical therapy should be attempted before considering sympathetic blocks, sympathectomy, or other invasive procedures.

    • State which conservative therapies were used and the duration of each.
    • Use Budapest Criteria documentation to confirm diagnosis prior to invasive therapies when applicable.
    Documentation Required

    Document trials of movement representation and physiotherapy before invasive procedures

    Conservative therapies such as graded motor imagery, mirror therapy, and physiotherapy‑based interventions are reasonable early options prior to invasive procedures; document trial and response to these modalities when claiming refractory status.

    • Provide details of motor imagery or mirror therapy programs (duration, frequency) and measured outcomes.
    • Note that evidence quality is low to very low, but these are recommended conservative options before invasive therapy.
    Step Therapy

    No explicit step‑therapy sequences specified in this excerpt

    The policy excerpt does not define explicit step therapy sequences or mandated order of conservative therapies; there are no prespecified step therapy requirements in this portion of the document.

    • While no mandated sequences are provided, document prior conservative therapies and rationale for chosen escalation pathways.
    • Providers should still supply evidence of attempted conservative care when requesting advanced interventions.
    Documentation Required

    Provide prior conventional therapy attempts before adjunctive/novel therapies

    The document expects that adjunctive or novel therapies be considered after standard therapies; provide documentation of prior attempts and responses to conventional treatments before requests for experimental or combined approaches.

    • For combined DRG and DCS or novel device use, include supporting trial/case series evidence and prior standard therapy history.
    • Explain why standard interventions (PT, medications) were inadequate.
    Step Therapy

    Step therapy requirements not specified in this section

    The policy expressly notes that no formal step therapy requirements are described in this portion of the bulletin; absence of step therapy language means clinicians must still document prior conservative care but are not bound to a mandated sequence here.

    • Confirm any payer‑specific step therapy rules separately, as this bulletin does not establish them.
    • Provide complete conservative treatment history with authorization requests.
    Documentation Required

    Required clinical documentation: pain history, conservative therapy, and block results

    Clinical documentation must include duration of pain, prior conservative therapies (exercises, PT, medications), results of nerve block trials, and enrollment in a comprehensive pain management program when repeat sympathetic blocks or continuous epidural analgesia are requested.

    • For continuous epidural analgesia, confirm pain >3 months, failed PT, and failed nerve block trials.
    • When requesting repeat sympathetic blocks beyond three injections, include evidence of the comprehensive pain program components.
    Documentation Required

    Document prior conservative failure and treatment‑resistant designation for refractory therapies

    When requesting refractory treatments such as anesthetic‑dose ketamine or DRGS, include detailed documentation of prior conservative treatment failure, designation of treatment‑resistant status, and specific dosing/course details for infusions.

    • For ketamine infusions, include infusion duration, dose escalation plan, and prior conservative therapies attempted.
    • State why the patient qualifies as treatment‑resistant or refractory.
    Documentation Required

    Documentation required for IV therapy requests: baseline scores and monitoring

    For IV therapies (e.g., ketamine), include objective baseline pain scores and functional measures and monitoring details because many IV therapy trials enrolled refractory patients with documented baseline measures.

    • Provide baseline VAS/NRS scores and functional assessments.
    • Describe monitoring during infusion (ECG, pulse oximetry, BP monitoring frequency) as used in outpatient protocols.
    Documentation Required

    Provide supporting documentation: diagnosis, prior treatments, and trial outcomes

    Recommended supporting documentation for advanced or investigational interventions includes prior conservative therapy attempts, CRPS diagnosis consistent with Budapest Criteria, prior treatment failures, and trial stimulation outcomes for device requests.

    • Attach Budapest Criteria assessment or equivalent documentation to support diagnosis.
    • Include trial stimulation outcomes, percentage pain relief, and device‑related follow‑up when applicable.
    Documentation Required

    Include clinical trial evidence and outcome measures for investigational device requests

    When requesting DRG stimulation or other investigational interventions, include clinical trial evidence and outcome measures (e.g., VAS/NRS scores, percentage pain relief, trial‑to‑permanent success) to support the request.

    • Reference available RCT or cohort evidence where applicable (ACCURATE trial for DRGS used ≥50% VAS reduction threshold).
    • Supply device trial reports and follow‑up outcome data.
    Documentation Required

    Document CRPS diagnosis using Budapest Criteria

    Clinical documentation must support a CRPS diagnosis using the Budapest Criteria (documenting symptoms and signs across sensory, vasomotor, sudomotor/edema, and motor/trophic categories and exclusion of alternate diagnoses).

    • Include recorded signs/observations and reported symptoms that map to Budapest Criteria categories.
    • Document exclusion of other diagnoses that better explain the findings.
    Note

    Administrative note — policy bulletins do not guarantee coverage

    Clinical Policy Bulletins assist in benefit administration and do not guarantee coverage; treating providers remain responsible for medical advice and must follow plan‑specific authorization and documentation requirements.

    • Policy statements do not constitute contract or guarantee of benefits; verify member benefits and authorization requirements separately.
    Denial Risk

    Denial risk if epidural analgesia criteria not met

    Continuous epidural analgesia is medically necessary only when all selection criteria are met (pain >3 months despite conservative therapy, failed PT, failed nerve blocks); otherwise it is considered experimental/investigational and may be denied.

    • Ensure documentation demonstrates each required selection criterion before billing for continuous epidural analgesia.
    • If criteria are not met, expect the treatment to be considered experimental/investigational and at risk for denial.
    Denial Risk

    Denial risk for excessive sympathetic block frequency or lack of benefit

    Sympathetic blocks beyond three injections without documented therapeutic benefit, or repeated outside a comprehensive pain program, may be denied; do not repeat more frequently than once every 7 days.

    • Initial trial limited to up to 3 injections to establish diagnosis/therapeutic effect.
    • If no relief after three injections, additional injections are not medically necessary and may be denied.
    Denial Risk

    Denial risk for therapies without well‑designed RCT evidence

    Treatments lacking supportive RCT evidence (many interventions reviewed) may be considered unsupported by evidence and are subject to denial if billed as proven therapies; provide high‑quality evidence when seeking coverage for such interventions.

    • Interventions without adequate RCT support (e.g., numerous listed investigational therapies) should include supporting peer‑reviewed evidence in requests.
    • Expect additional review or denial when robust evidence is absent.
    Denial Risk

    Denial risk for sympathectomy without clear prior therapy failure

    Sympathectomy (chemical or surgical) should be used cautiously and generally only after failure of other treatment options; lack of high‑quality evidence may lead to denial if attempted earlier or broadly.

    • Because randomized, controlled evidence is minimal, justify sympathectomy with prior conservative treatment failure and case‑by‑case rationale.
    • Anticipate careful review and potential denial without documented prior management attempts.
    Denial Risk

    Evidence limitations may trigger additional review or denial

    Evidence limitations — including high heterogeneity, variable dosing/duration, small sample sizes, and short‑term benefits (e.g., ketamine pain relief often <3 months) — may trigger documentation requests or denial for routine coverage without supporting clinical rationale.

    • Meta‑analyses and systematic reviews note heterogeneity and short duration of effect for IV ketamine; include clinical rationale and monitoring data.
    • Provide long‑term outcome data where available to support coverage.
    Note

    No specific authorization/coding denial triggers listed here

    The excerpt does not specify explicit authorization or coding‑based denial triggers beyond the general statements above; verify payer‑specific coding and authorization policies.

    • No additional coding‑based denial triggers are specified in this portion of the policy.
    • Confirm plan‑specific utilization management rules when submitting claims.
    Denial Risk

    Insufficient peer‑reviewed evidence may lead to denial for proprietary devices

    Lack of peer‑reviewed published data for certain proprietary devices or novel therapies (e.g., Sanexas electroanalgesia) may lead to noncoverage or denial when billed without supporting evidence.

    • When proposing use of devices with limited peer‑reviewed data, include any available studies and justify clinical rationale.
    • Expect denials in the absence of published supporting evidence.
    Note

    No administrative denial triggers specified; verify plan applicability

    Administrative denial risks are not detailed in this section; policy history and review dates are provided which may affect applicability — check plan dates and member benefits for current applicability.

    • Policy last reviewed 02/27/2024; verify member eligibility and policy version at time of service.
    • Administrative or benefit‑limit denials are managed per plan documents, not by this CPB text alone.

    Definitions and Diagnostic Criteria

    Continuous epidural analgesia — definition and typical hospitalization
    DefinitionContinuous epidural analgesia: continuous infusion of analgesic agents via an epidural catheter for intractable CRPS after failure of conservative measures.
    Typical hospital stayOften requires hospitalization, typically 4–6 days, for continuous epidural narcotic analgesia to break the pain cycle.
    PrerequisitesConsidered medically necessary only when pain >3 months despite conservative therapy, failed PT, and failed trial of nerve blocks with local anesthetic and steroids.
    Sympathetic blocks — definition
    DefinitionSympathetic blocks (e.g., stellate ganglion, lumbar sympathetic block): local anesthetic injections targeting sympathetic ganglia used for diagnosis and short-term treatment of sympathetically-maintained pain/CRPS.
    Diagnostic utilityMay provide short-term pain decrease useful for diagnosis and facilitating mobilization of the affected limb.
    Frequency guidanceMay be performed at one-week intervals; abandon if immediate response not observed after first or second block per clinical guidance.
    CRPS-1 and CRPS-2 distinction
    CRPS-1 (formerly RSD)CRPS-1: syndrome without an identified nerve injury (most patients).
    CRPS-2 (formerly causalgia)CRPS-2: syndrome with an identified partial nerve lesion or documented nerve injury.
    Distinguishing featurePresence or absence of a partial nerve lesion distinguishes CRPS-1 from CRPS-2.
    CRPS subtypes (CRPS-I vs CRPS-II)
    CRPS-I vs CRPS-IICRPS-I (no identifiable nerve injury) versus CRPS-II (identifiable nerve injury) — clinical distinction based on presence of nerve lesion.
    TerminologyCRPS-I formerly called reflex sympathetic dystrophy; CRPS-II formerly called causalgia.
    Implication for studiesSome investigational treatments and evidence summaries differentiate results by CRPS subtype; diagnosis is clinical and multifactorial.
    Procedural definitions — neurolysis/sympathectomy
    NeurolysisNeurolysis: chemical or surgical destruction/interruption of nerve tissue (e.g., phenol neurolysis) intended to reduce pain; pilot data exist but larger trials needed.
    SympathectomySympathectomy: chemical or surgical interruption of the sympathetic chain (e.g., surgical or RF sympathectomy); should be used cautiously and usually only after other options fail.
    Evidence cautionSurgical/chemical sympathectomy practice is based on limited high-quality evidence; consider case-by-case and registry when used.
    Ketamine infusion definition/parameters
    DefinitionKetamine infusion: intravenous administration of ketamine at sub-anesthetic to anesthetic dosages over multi-day courses (various protocols reported, e.g., 4-hour infusions daily x10 days; max reported infusion rate 0.35 mg/kg/hr in one RCT).
    Duration/parametersReported study protocols vary (e.g., 4-hr daily infusions x10 days; multi-day courses of 3–4 days reported in other series); dosing strategies and durations are heterogeneous across studies.
    Effectiveness noteMeta-analyses and trials show short-term pain reduction (typically <3 months) with heterogeneity; high-quality evidence for long-term benefit is limited.
    Dorsal Root Ganglion Stimulation (DRGS) definition
    DefinitionDorsal Root Ganglion Stimulation (DRGS): neuromodulation technique placing percutaneous leads near dorsal root ganglia to provide targeted electrical stimulation for neuropathic pain including CRPS.
    PurposeProvides targeted pain–paresthesia concordance, enabling stimulation of areas difficult to cover with traditional SCS and reported to improve pain and quality of life in cohorts.
    Trial-to-implant approachDRGS typically involves a trial stimulation phase; successful trials may proceed to permanent implantation and programming.
    DRGS — neurostimulation targeting DRG
    TargetingDRGS targets the dorsal root ganglia with percutaneously placed epidural leads to achieve precise pain–paresthesia overlap and reduced postural variation in paresthesia.
    Clinical evidenceACCURATE randomized trial and cohort studies report higher rates of >=50% pain relief and better targeting versus dorsal column stimulation for lower-extremity CRPS.
    Implantation noteLead placement is performed with conventional percutaneous techniques; documentation should include targeted levels and trial outcomes.
    Intravenous Immunoglobulin (IVIG) definition
    DefinitionIntravenous immunoglobulin (IVIG): systemic immune-modulating therapy delivered intravenously; evaluated in CRPS in randomized trials.
    Study resultA randomized multicenter double-blind trial of low-dose IVIG (0.5 g/kg) in long-standing CRPS showed no significant pain reduction versus placebo.
    ImplicationRoutine use not supported for moderate-to-severe long-standing CRPS based on trial results; further study needed for selected patients.
    Budapest Criteria — diagnostic criteria for CRPS
    Purpose of CriteriaThe Budapest Criteria are the clinical diagnostic criteria used to make a diagnosis of CRPS based on history and physical examination.
    Core requirementsContinuing disproportionate pain plus at least one reported symptom in each of four categories (sensory, vasomotor, sudomotor/edema, motor/trophic).
    Observed signs and exclusionAt least one observed sign in two or more categories is required at evaluation, and no other diagnosis should better explain the signs and symptoms.
    Budapest Criteria — additional details
    Symptom categoriesSymptoms must include at least one in each category: Sensory, Vasomotor, Sudomotor/Edema, Motor/Trophic.
    Sign requirementsMust display at least one sign at evaluation in two or more categories (e.g., hyperalgesia/allodynia; temperature asymmetry; edema; decreased range of motion).
    No alternative diagnosisDiagnosis excludes any other diagnosis that better explains the signs and symptoms.

    Conservative Treatment and Prerequisites

    inv-74: Failed conservative therapy and failed PT required (> 3 months)

    Documented conservative therapy prerequisites for certain advanced interventions:

    Failed conservative therapy and PT requirement: Members must have pain > 3 months despite conservative therapy (eg, exercises, physical modalities, medications) AND must have failed a trial of physical therapy prior to consideration of continuous epidural analgesia or escalation to certain interventional therapies.> 3 months

    Document prior conservative treatments and responses in the medical record.

    inv-75: Failure of conservative treatments (documentation required)

    Documentation required to support failure of conservative treatments before interventional procedures:

    Failure of conservative treatments (documentation): Prior conservative treatments (eg, analgesics, physical therapy, graded motor imagery where applicable) must have been tried and documented as ineffective or insufficient to control pain or improve function before sympathetic blocks, continuous epidural analgesia, or neuromodulation are pursued.

    Records should include duration, modalities tried, and objective measures of response (eg, pain scores, functional limitations).

    inv-76: Document prior conservative therapy failure before advanced interventions.

    Prior conservative therapy failure should be documented before advanced interventions and device implantation:

    Document prior conservative therapy failure before advanced interventions: Provide documentation of prior conservative therapy attempts and insufficient response before considering advanced interventions (eg, DRG stimulation, SCS, multi-day ketamine infusions); for device implantation, include results of successful trial stimulation.

    Refer to CPB 0194 for device-specific trial-to-implantation documentation requirements.

    inv-78: Document failure of conservative measures prior to invasive neuromodulation or anesthetic-dose ketamine.

    Document conservative therapy failure prior to considering invasive neuromodulation or anesthetic-dose ketamine:

    Conservative measures before invasive neuromodulation/ketamine: Document failure of conservative measures (eg, PT, graded motor imagery, adequate trials of oral analgesics and neuropathic agents) before pursuing invasive neuromodulation (eg, DRGS/SCS) or anesthetic-dose ketamine infusions.

    Clinical records should include objective baseline pain scores and prior treatment durations and responses.

    inv-79: Conservative treatment nodes (placeholder)

    Conservative treatment components that may be considered in documenting prior therapy attempts:

    Conservative treatment options: Physical therapy/exercise programs; graded motor imagery/mirror therapy; occupational therapy; oral analgesics including neuropathic agents; short courses of steroids where appropriate; bisphosphonates when bone loss is documented; patient education and psychosocial support as part of a comprehensive pain program.

    Document specific modalities, durations, and objective measures of effect or failure.

    inv-80: Document prior conservative therapy attempts and trial stimulation success for device implantation requests.

    Requirements for device implantation requests:

    Device implantation documentation: For requests for permanent neurostimulation device implantation, document prior conservative therapy attempts AND a successful trial stimulation (with objective pain reduction and absence of stimulation-related neurological deficits) before proceeding to permanent implant.Trial stimulation success typically defined per device trial protocol (eg, >=50% pain relief in pivotal trials)

    Refer to CPB 0194 and ACCURATE trial metrics for DRG/SCS trial success definitions.

    inv-81: Section does not specify conservative treatment requirements; references literature and guidelines.

    Notes regarding conservative treatment requirements in this section:

    Policy-level note on conservative requirements: This section of the policy does not specify exhaustive stepwise conservative treatment sequences; instead it references clinical guidelines and literature emphasizing failure of appropriate conservative measures prior to advanced or investigational therapies.

    Providers should supply documentation of prior therapies and rationale when requesting advanced interventions.

    Frequency and Quantity Limits

    Sympathetic blocks — repeat interval and trial
    Repeat interval limitSympathetic blocks should not be repeated more frequently than once every 7 days.
    Initial trialUp to 3 initial sympathetic blocks are considered medically necessary to establish diagnosis/therapeutic effect.
    Subsequent useAdditional injections beyond 3 are medically necessary only as part of a comprehensive pain program with documented benefit.
    Spinal cord stimulator implant/test and permanent placement — guidance
    Trial and permanent placementSpinal cord stimulator or DRG systems generally require a successful trial stimulation before permanent implantation; documentation of trial success and prior conservative therapy is expected.
    Frequency guidanceNo explicit numeric frequency limits for repeat trials/implants are provided in this excerpt; refer to CPB 0194 for detailed SCS implantation criteria.
    Prior therapy requirementRequests should document failure of conservative therapies (e.g., PT, medications) prior to device implantation.
    Sympathetic (stellate or lumbar) blocks — initial trial
    Initial trial allowanceUp to 3 initial sympathetic (stellate or lumbar) blocks are considered medically necessary as a diagnostic/therapeutic trial.
    Abandonment guidanceTreatment should be abandoned if immediate response (improved temperature or decreased pain) does not occur following the first or second block per clinical guidance.
    Comprehensive program requirementFurther blocks beyond the initial trial are authorized only within a comprehensive pain management program with documented benefit.
    Ketamine infusion courses — dosing/duration and limits
    Variability in protocolsKetamine infusion courses studied vary widely in dose and duration (examples include 4-hour daily infusions x10 days or multi-day low-dose courses); no single frequency limit is specified in the policy excerpt.
    Short-term benefitMeta-analyses indicate ketamine infusions can provide clinically effective short-term pain relief (typically <3 months) though heterogeneity exists.
    Documentation/monitoringClinical documentation should include prior conservative therapy failure, baseline pain scores, and monitoring during infusion (e.g., ECG, pulse oximetry) as described in trial protocols.
    DRG stimulation trial and permanent implantation notes
    DRG trial-to-implantDRG stimulation requires a trial stimulation; permanent implantation is typically performed after documented successful trial stimulation and failure of conservative therapies.
    Evidence baseACCURATE randomized trial supports DRGS efficacy for lower-extremity CRPS; documentation of trial outcome and targeted levels should accompany implant requests.
    No explicit revisit frequencyThe excerpt does not specify numeric frequency limits for repeat DRG trials or re-implantation procedures.
    Frequency limits — neuromodulation / PNS procedures
    Frequency limits absentNo explicit frequency limits for neuromodulation (including DRG, SCS) or percutaneous PNS procedures are provided in this policy excerpt.
    Documentation expectationRequests for implantation should include documentation of prior conservative therapy failure and trial stimulation success.
    Refer to device-specific policiesRefer to CPB 0194 and device-specific guidance for detailed implantation and coverage criteria.
    Reference section — frequency limits not specified
    Reference section noteThe policy reference section does not specify frequency limits for procedures; refer to cited literature and device-specific policy for details.
    Use citations for clinical detailsClinical protocols and frequency considerations are described in source studies and device guidance rather than as fixed policy limits in this excerpt.
    Next reviewPolicy literature and recommendations may be updated at subsequent reviews; check referenced RCTs and CPB updates.

    Imaging and Procedural Guidance

    Billing Rule

    Use fluoroscopy/CT for specified epidural, transforaminal, and neurostimulator procedures

    Epidural injections, transforaminal injections, and neurostimulator electrode placement codes indicate imaging guidance (fluoroscopy or CT) where specified in coding descriptors; perform and document imaging guidance for those codes.

    • 62327 and 64479–64484 specify fluoroscopy or CT guidance.
    • Neurostimulator electrode placement codes reference fluoroscopy when performed.
    Documentation Required

    Monitoring requirements during ketamine infusions (ECG, SpO2, BP q15min)

    Ketamine infusion protocols described in outpatient studies included continuous ECG, pulse oximetry, and non-invasive blood pressure monitoring every 15 minutes during infusions; document monitoring used.

    Documentation Required

    Obtain MRI as indicated to exclude alternative diagnoses

    MRI may be useful to exclude alternative diagnoses and should be used as part of the diagnostic workup when indicated; document imaging findings when used to support CRPS evaluation.

    Documentation Required

    Document DRGS lead placement and targeted levels

    DRGS implantation documentation should include lead placement details and the targeted levels (e.g., lumbar leads for knee CRPS such as L2–L4) and report trial stimulation results.

    • Document number and location of percutaneous leads.
    • Include trial outcome and programming/coverage notes.
    Documentation Required

    DRG lead placement: document percutaneous technique and imaging guidance

    DRG lead placement in published series used conventional percutaneous techniques with imaging guidance implied; when applicable document imaging guidance and lead targeting.

    Billing Rule

    Use and document imaging guidance for percutaneous PNS when performed

    For percutaneous peripheral nerve stimulation (PNS), published reports recommend using imaging (e.g., ultrasound) when described; document imaging guidance if used for needle/lead placement.

    Note

    No general imaging prerequisites specified — follow procedure-specific guidance

    No specific imaging prerequisites are provided in this part of the document for other therapies; follow code descriptors and local standards and document any imaging performed.

    Not Covered / Experimental Therapies

    The policy identifies a broad list of experimental and investigational therapies that are not supported by current peer‑reviewed evidence or guideline summaries. Examples include (but are not limited to) Sanexas electroanalgesia, intrapleural analgesia, propofol infusions for CRPS, various novel neuromodulation combinations, BEMER magneto‑therapy, prism adaptation, and other techniques not described in UpToDate or lacking robust RCT data. These approaches should be considered investigational and are not covered as standard treatments for CRPS pending adequate supporting evidence.

    Duplicate listing: items listed among investigational therapies are not considered standard of care and lack sufficient peer‑reviewed evidence; billing for such modalities may be denied without adequate supporting clinical data.

    Duplicate listing: specific devices and therapies described in background (for example, Sanexas electroanalgesia) are highlighted as lacking peer‑reviewed published data and remain investigational.

    Duplicate listing: procedures and technologies without controlled evidence (including some noninvasive stimulation devices and novel physical modalities) are considered investigational in this policy.

    Duplicate listing: investigational interventions enumerated in the policy should be evaluated in properly designed randomized trials before routine clinical adoption.

    Duplicate listing: therapies without adequate supporting data are included in the policy's investigational list and are not standard treatments for CRPS.

    Duplicate listing: absent convincing clinical trial evidence, these interventions remain investigational and are not covered for CRPS indications in the policy.

    Duplicate listing: providers should supply robust peer‑reviewed evidence when requesting coverage for these non‑standard therapies.

    Duplicate listing: absence from major evidence summaries such as UpToDate is a signal of insufficient evidence for routine use.

    Duplicate listing: investigational interventions described in device or small pilot reports require confirmatory RCTs prior to being supported for routine CRPS care.

    Duplicate listing: items enumerated in the investigational list remain subject to policy review as new evidence becomes available.

    Low‑dose IVIG (0.5 g/kg) did not show benefit in a randomized trial for long‑standing CRPS and is not supported for routine use. BEMER magneto‑therapy showed short‑term improvements in a small pilot RCT but remains investigational pending larger, confirmatory studies; both are therefore listed as investigational in this policy.

    Duplicate listing: as above, treatments without sufficient published evidence are considered investigational and are not standard therapeutic options for CRPS.

    Duplicate listing: absence of robust controlled clinical data places these therapies in the investigational category.

    Duplicate listing: investigational status should be revisited if high‑quality randomized data become available.

    Background and Evidence Overview

    Complex Regional Pain Syndrome (CRPS), also known as Reflex Sympathetic Dystrophy (RSD), is a chronic neuropathic pain disorder that often follows trauma and is characterized by continuing disproportionate pain, autonomic changes, and motor/trophic disturbances. Management emphasizes a conservative, multidisciplinary approach (e.g., physical therapy, analgesics, motor/sensory retraining), with interventional therapies considered for refractory cases. Dorsal root ganglion stimulation and other neuromodulation approaches have emerging evidence in selected patients, but many other interventions remain experimental or supported only by small trials.

    Evidence summaries and considerations in the policy highlight that some interventions (for example, ketamine infusions, bisphosphonates, IVIG, and neuromodulation) have shown short‑term or condition‑specific benefits in small trials or pooled analyses, but overall the literature is limited by small sample sizes, heterogeneity of dosing and populations, and inconsistent functional outcomes. These limitations affect coverage determinations: interventions with consistent, high‑quality RCT evidence or guideline support may be considered under specified criteria, whereas therapies supported only by small or negative trials are treated as investigational or not medically necessary.

    Policy Revision History